| Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR) M Ramos-Casals, A Maria, ME Suárez-Almazor, O Lambotte, BA Fisher, ... Clin Exp Rheumatol 37 (Suppl 118), 114-22, 2019 | 97 | 2019 |
| Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors J Aldrich, X Pundole, S Tummala, N Palaskas, CR Andersen, M Shoukier, ... Arthritis & Rheumatology 73 (5), 866-874, 2021 | 83 | 2021 |
| Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation XN Pundole, AG Barbo, H Lin, RE Champlin, H Lu Journal of Clinical Oncology 33 (12), 1364-1370, 2015 | 55 | 2015 |
| Arthritis risk with immune checkpoint inhibitor therapy for cancer X Pundole, N Abdel-Wahab, ME Suarez-Almazor Current opinion in rheumatology 31 (3), 293-299, 2019 | 46 | 2019 |
| Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation N Chanson, M Ramos-Casals, X Pundole, K Suijkerbuijk, MJB e Silva, ... European Journal of Cancer 158, 208-216, 2021 | 37 | 2021 |
| Cancer and rheumatoid arthritis X Pundole, ME Suarez-Almazor Rheumatic Disease Clinics 46 (3), 445-462, 2020 | 34 | 2020 |
| Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis X Pundole, HI Cheema, G Sanchez-Petitto, MA Lopez-Olivo, ... Bone marrow transplantation 52 (5), 663-670, 2017 | 24 | 2017 |
| Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal … ME Suarez-Almazor, X Pundole, N Abdel-Wahab, DB Johnson, D Gupta, ... Supportive Care in Cancer 28, 6159-6173, 2020 | 21 | 2020 |
| Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia: a case report X Pundole, S Konoplev, TH Oo, H Lu Medicine 94 (19), e741, 2015 | 17 | 2015 |
| Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation X Pundole, WA Murphy, CC Ebede, E Karim, S Manocha, D Don-Pedro, ... Archives of Osteoporosis 13, 1-8, 2018 | 14 | 2018 |
| Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional … ME Suarez-Almazor, X Pundole, G Cabanillas, X Lei, H Zhao, LS Elting, ... JAMA network open 5 (4), e225432-e225432, 2022 | 13 | 2022 |
| Cervical cancer screening in women with systemic lupus erythematosus S Bruera, X Lei, R Zogala, X Pundole, H Zhao, SH Giordano, JP Hwang, ... Arthritis Care & Research 73 (12), 1796-1803, 2021 | 13 | 2021 |
| Role of varicella zoster virus in glioma risk: current knowledge and future directions X Pundole, ES Amirian, ME Scheurer OA Epidemiol 2 (6), 2014 | 13 | 2014 |
| Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis ST Kim, X Pundole, R Dadu, O Lambotte, M Ramos-Casals, ... Immunotherapy 13 (6), 465-475, 2021 | 12 | 2021 |
| Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy X Pundole, NV Zamora, H Siddhanamatha, H Lin, J Tayar, CH Leung, L Li, ... Clinical rheumatology 39, 2943-2950, 2020 | 12 | 2020 |
| Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report X Pundole, AL Jones, MT Tetzlaff, MD Williams, WA Murphy Jr, A Otun, ... Immunotherapy 12 (17), 1213-1219, 2020 | 11 | 2020 |
| Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer X Pundole, NV Zamora, H Siddhanamatha, H Lin, J Tayar, LC Hong, L Li, ... Clinical Rheumatology 39, 787-794, 2020 | 10 | 2020 |
| Rheumatic and musculoskeletal adverse events with immune checkpoint inhibitors: data from the United States Food and Drug Administration adverse event reporting system XN Pundole, M Sarangdhar, ME Suarez-Almazor Journal of Immunotherapy and Precision Oncology 2 (3), 65-73, 2019 | 10 | 2019 |
| The role of bone modifying agents in myeloma bone disease H Lu, X Pundole, HC Lee Journal of Bone and Mineral Research Plus 5 (8), e10518, 2021 | 7 | 2021 |
| José de Barros E Silva M, Lidar M, et al.; ICIR. Immune checkpoint inhibitor–associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation N Chanson, M Ramos-Casals, X Pundole, K Suijkerbuijk Eur J Cancer 158, 208-216, 2021 | 7 | 2021 |
